CRP and cardiovascular disorder: C-reactive protein (CRP) is a frequently used marker of systemic inflammation, the latest landmark CANTOS trial showed those with CRP concentrations less than 2 mg/L achieved by canakinumab treatment (a monoclonal antibody targeting interleukin 1β) had a 25% reduction of major adverse cardiovascular events, which indicated the prognostic value of CRP in primary and secondary prevention of cardiovascular diseases [12].